Therapeutic modulation of growth factors and cytokines in regenerative medicine

Current Pharmaceutical Design

Volumn 12, Issue 19, 2006, Pages 2397-2408

  Ioannidou, Effie ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Cytokines; Growth factors; Regenerative medicine; Stem cells

Indexed keywords

ACTIVIN A; ALPHA2A INTERFERON; BETACELLULIN; BEVACIZUMAB; BONE MORPHOGENETIC PROTEIN; CYTOKINE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; KERATINOCYTE GROWTH FACTOR; NERVE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLEIOTROPHIN; POLYMER; SOMATOMEDIN B; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ALZHEIMER DISEASE; ANGIOGENESIS; BONE REGENERATION; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL DIVISION; CELL FUNCTION; CELL GROWTH; CELL LINEAGE; CELL REGENERATION; CELL RENEWAL; CELL TYPE; CLINICAL TRIAL; COLORECTAL CANCER; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ENDOTHELIUM CELL; EPITHELIUM CELL; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEMATOPOIESIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREGULATION; INTRAMEDULLARY NAILING; MESENCHYME CELL; MULTIPLE SCLEROSIS; NERVE REGENERATION; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PERIODONTAL DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REGENERATIVE MEDICINE; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; STOMATITIS; SYSTEMATIC REVIEW; TARGET CELL; TIBIA FRACTURE; TISSUE ENGINEERING; TISSUE REGENERATION;

ANIMALS; CYTOKINES; GROWTH SUBSTANCES; HUMANS; REGENERATIVE MEDICINE;

EID: 33745746818     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206777699007     Document Type: Review

References (133)

1. Donovan PJ, Gearhart J. The end of the beginning for pluripotent cells. Nature 2001; 414: 92-97.
2. Ferrari G, Cusella-De Angellis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528-1530.
3. Brazelton TR, Rossi FM, Keshet GI, Blau HM. From marrow to brain: expression of neuronal phenotypes in adult mice. Science 2000;290: 1775-1779.
4. Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dolise M, Osborne L, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 2000:6: 1129-1234.
5. Hirschi KK, Goodell MA. Hematopoietic, vascular and cardiac fates of bone marrow-derived stem cells. Gene Ther 2002; 9: 648-652.
6. Bianco P, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology and potential applications. Stem Cells 2001; 19: 180-192.
7. Pittenger W, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284(5411): 143-7.
8. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418(6893): 41-9.
9. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981; 292: 154-156.
10. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Wakintz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocytes Science 1998; 282: 1145-1147.
11. Watt FM, Hogan Bl. Out of Eden: stem cells and their niches. Science 2000; 287: 1427-1230.
12. Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol 2000; 18: 399-404.
13. Onishi M, Nosaka T, Kitamura T. Cytokine receptors: structures and signal transduction. Int Rev Immunol 1998; 16(5-6): 617-634.
14. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2): 277-85.
15. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27-31.
16. Zwaginga JJ, Doevendans P. Stem cell-derived anglogenic/vasculogenic cells: Possible therapies for tissue repair and tissue engineering. Clin Exp Pharmacol Physiol 2003; 30: 900-908.
17. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1585.
18. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992; 182: 824-831.
19. Folknum J. Clinical applications of research on angiogenesis. N Eng J Med 1995; 333(26): 1757-1763.
20. Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B, et al. Rescue of diabetes-related impairement of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 1999; 154:185-190.
21. Waltenberger J, Lange J, Kranz A. Vascular endothelial growth factor-A-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus: A potential predictor for the individual capacity to develop collaterals. Circulation 2000; 102: 185-190.
22. O'Brien ER, Garvin MR, Dev R. Angiogenesis in huntan coronary atherosclerotic plaques. Am J Pathol 1994; 145: 883-894.
23. Starvi GT, Hong Y, Zachary IC, Breier G, Baskerville PA, Yla-Herttuala S, et al. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett 1995; 358:311-315.
24. Welterman A, Wolzt M, Petersmann K, Czemi C, Grazelli U, Lechner K, et al. Large amounts of vascular endothelial growth factor at the site of hemostatic plug formation in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 1757-1760.
25. Galiano RD, Tepper OM, Pelo CR, Bhatt KA, Callaghan M, Bastidas N, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004; 164(6): 1935-47.
26. Shintani S, Murohara T, Ikeda H, Ueno T, Houma T, Katoh A, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103: 2776-2779.
27. Nugent HM, Edelman ER. Tissue engineering therapy for cardiovascular disease. Circ Res 2003: 92: 1068-1078.
28. Ying QL, Nichols J, Evans EP, Smith AG. Changing potency by spontaneous fusion. Nature 2002; 416:545-548.
29. Kawamoto A, Gwon HC, Iwaguro, H, Yamaguchi JI, Uchida S, Masuda H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001; 103: 634-637.
30. Aeillo LP, Avery RL, Arrigg RG. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331: 1480-1487.
31. White CW, Sondheimer HM, Crouch EC, Wilson H, Fan LL. Treatment of pulmonary hemangioma of infancy. N Engl J Med 1992;326: 1456-1463.
32. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemagiomas of infancy. N Eng J Med 1992; 326: 1456-1463.
33. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-586.
34. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21(1): 60-5.
35. Huang J, Frischer JS, Serur A, Kadenhe A, Yokoi A, McCrudden KW, et al. Regression of establishment tumors and metastasis by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003; 100: 7785-7790.
36. Thomas AL, Morgan B, Drevs J, Unger C, Wiedenmann B, Vanhoefer U, et al. Vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Oncol 2003; 30: 32-38.
37. Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF, et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Ann Rev Immunol 2003; 21: 759-806.
38. Papayannopoulou. T. Hematopoietic stem/progenitor cell mobilization. A continuing quest for etiologic mechanisms. Ann NY Acad Sci 1999; 872: 187-199.
39. Levesque JP, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ. Mobilization by either cyclophosphamide or granulacyte colony-stmulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002;30: 440-449.
40. Linch DC, Milligan DW, Winfield DA, Kelsey SM, Johnson SA, Littlewood TJ, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNL1 trial. Br J Haematol 1997; 99(4); 933-938.
41. Piccirillo N, Sora F, Laurenti L, Chiusolo P, Serafini R, Ciccom S, et al. Kinetics of hemopoietic recovery after peripheral blood stem cell transplantation: impact of stem cell purification and G-CSF. Am J Hematol 2002; 69: 7-14.
42. Schwab ME, Bartholdi D. Degeneration and regeneration of axons in the lesioned spinal cord. Physiol Rev 1996; 76: 319-370.
43. Bareyre FM, Kerschensteiner M, Raineteau O, Mettenleiter TC, Weinmann O, Schwab M. The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. Nat Neurosc 2004; 7(3):269-277.
44. Weidner N, Ner A, Salimi N, Tuszynski MH. Spontaneous corticospinal axonal plasticity and functional recovery after adult central nervous system injury. Proc Natl Acad Sci USA 2001; 98: 3513-3518.
45. Martino G. How the brain repairs itself: new therapeutic strategies in inflammatory and degenerative CNS disorders. Lancet Neurol 2004; 3: 372-377.
46. Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, I: adult brain. Clin Exp Pharmacol Physiol 1999; 26: 11-19.
47. Mews I, Bergmann M, Bunkowski S, Gullotta F, Bruck W. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Mult Scler 1998; 4(2): 55-62.28.
48. Martino G, Adorini L, Rieckmann P, Hiltert J, Kallmann B, Comi G, et al. Inflammation in multiple sclerosis: the good, the bad and the complex. Lancet Neurol 2002; 1: 499-509.
49. Furlan R, Brambilla E, Ruffini F, Polliani PL, Bergami A, Marconi PC, et al. Intrathecal delivery of IFN-gamma protects C57BL/6 mice from chronic-progressive experimental autoinumine encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J Immunol 2001; 167: 1821-1829.
50. Carpenter MK, Chui X, Hit ZY, Jackson J, Sherman S, Seiger A, et al. In vitro expansion of a multipotent population of human neural progenitor cells. Exper Neurol 1999; 158: 383-397.
51. Storch A, Paul G, Csete M, Boehm BO, Carvey PM, Kupsch A, et al. Long-term proliferation and dopaminergic differentiation of human mesencephalic; neural precursor cells. Exper Neurol 2001; 170: 317-325.
52. Kordower JH, Chen EY, Chen EY, Winkler C, Fricker R, Charles V, et al. Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: tropbic and tropic effects in a rodent model of Huntington's disease. J Compar Neurol 1997; 387: 96-113.
53. Emerich DF, Bruhn S, Chu Y, Kordower JH. Cellular delivery of CNTF but not NT-4/5 prevents degeneration of stratial neurons in a rodent model of Huntington's disease. Cell Transplant 1998; 7: 213-225.
54. Rocca MA, Falini A, Colombo B, Scotti G, Comi G, Filippi M. Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with die extent of brain structural damage. Ann Neurol 2002; 51: 330-339.
55. Davies SJ, Fitch MT, Memberg SP, Hall AK, Raisman G, Silver J. Regeneration of adult axons in white matter tracts of the central nervous system. Nature 1997; 390: 680-683.
56. Kerscheensteiner M, Stadelmann C, Dechant G, Wekerle H, Hhlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 2003; 292-304.
57. Hurelbrick CB, Barker RA. Prospects for the treatment of Parkinson's disease using neurotrophic factors. Ex Opin Pharmacother 2001; 2: 1531-1543.
58. Aoi M, Date L, Tomita S, Ohmoto T. Single administration of GDNF into the stratum induced protection and repair of the nigrostratial dopaminergic system in the intrastratial 6-hydroxydopamine injection model of hemiparkinsonism. Rest neurol Neorsci 2001; 17:31-38.
59. Date L, Shingo T, Yoshida H, Fujiwara K, Kobayashi K, Takeuchi A, et al, Grafting of encapsulated genetically modified cells secreting GDNF into the stratum of parkinsonian model rats. Cell Transplant 2001; 10: 397-401.
60. Shingo T, Date L, Yoshida H, Ohmoto T. Neuroprotective and restorative effects of intrastratial grafting of encapsulated GDNF-producing cells in a rat model of Parkinson's disease. J Neurosci Res 2002; 69: 946-954.
61. Park KW, Eglitis MA, Mouradian MM. Protection of nigral neurons by GDNF-engineering marrow cell transplantation. Neurosci Res 2001; 40: 315-323.
62. Akerud P, Canals JM, Snyder EY, Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci 2001; 21: 8108-8118.
63. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 1986; 83: 9231-9235.
64. Rosenberg MB, Friedmann T, Robertson RC, Tuszynski M, Wolff JA, Breakefield XO, et al. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science 1988; 242: 1575-1578.
65. Chen KS, Gage FH. Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J Neurosci 1995; 15: 2819-2825.
66. Smith DE, Roberts J, Gage FH, Tuszynski MH. Non-tropic actions of neurotrophins: subcortical NGF gene delivery reverses agerelated degeneration of primate cortical cholinergic innervation. Proc Natl Acad Sci USA 1999; 98: 1941-1946.
67. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-852.
68. Arnett HA, Wang Y, Matsushima GK, Suzuki K, Ting JP. Functional genomic analysis of retriyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci 2003; 23: 9824-9832.
69. Brudin L, Brisman H, Danilov AI, Olsson T, Johansson CB. Neural stem cells: a potential source for remyelination in neuroinflarnmatory disease. Brain Pathol 2003; 13: 322-328.
70. Vela JM, Molina-Holgano E, Arevalo-Martin A, Almazim G, Guaza C. Interleukin-1 regulates proliferation and differentiation of oligodendrocyte progenitor cells. Mol Cell Neurosci 2002; 20: 489-502.
71. Bianco PPP, Robey PG. Stem cells in tissue engineering. Nature 2001; 414: 118-121
72. Pfeilschifter J, Bonewald L, Mundy GR. Chemotactic response of ostooblast like cells to transforming growth factor beta. J Bone Miner Res 1990; 5: 825-830.
73. Oreffo RO, Mundy GR, Seyedin SM, Bonewald LF. Activation of the bone-derived latent TGF beta complex by isolated osteoblasts. Biochem. Biochem Biophys Res Commum 1989; 158: 817-823.
74. Marcelli C, Yates AJ, Mundy GR. In vivo effects of human recombinant transforming growth factor beta on bone turnover in normal mice. J Bone Miner Res 1990; 5: 1087-1096.
75. Beck LS, Deguzman L, Lee WP, Xu Y, McFatridge LA, Gillett NA, et al. TGF-beta I induces bone closure of skull defects. J Bone Miner Res 1991; 6: 1257-1265.
76. Grainger DJ, Percival J, Chiano M, Spector TD. The role of serum TGF-beta isoforms as potential markers of osteoporosis. Osteoporos Int 1999; 9(5): 398-404.
77. Shaarawy M, Zaki S, Sheiba M, El-Minawi AM. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis. Clin Lab 2003; 49(11-12): 625-36.
78. Wonzey JM, Rosen V. Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop 1998; 346: 26-37.
79. Yasko AW, Lane JM, Fellinger EJ, Rosen V, Wonzey JM, Wang EA. The healing of segmental bone defects, induced by recombinant human bone morphogenetic protein (rhBMP). A radiographic, histological, and biomechanical study in rats. J Bone Joint Surg Am 1992; 72: 659-670.
80. Hollinger JO, Schmitt JM, Buck DC, Shannon I, Job SP, Zergula HD, et al. Recombinant human bone morphogenetic protein-2 and collagen for bone regeneration. J Biomed Mater Res 1998; 43: 356-364.
81. Boden SD, Sumner DR. Biologic factors affecting spinal fusion and bone regeneration. Spine 1995; 20(24 Suppl): 102S-112S.
82. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, et al. BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 2002; 84-A(12): 2123-34.
83. Yang X, Tare RS, Partidge KA, Roach HI, Clarke NM, Howdle SM, et al. Induction of human osteoprogenitor chemotaxis, proliferation, differentiation and bone formation by osteoclast stimulating factor-1/ pleiotrophin: osteoconductive biomimetic scaffolds for tissue engineering. J Bone Miner Res 2003; 18: 47-457.
84. Tare RS, Oreffo RO, Sato K, Rauvala H, Clarke NM, Roach HI. Pleitrophin/ osteoblast-stimulating factor-1: dissecting its diverse functions in bone formation. J Bone Miner Res 2002; 17: 2009-2020.
85. Mohan S, Baylink DJ. Insulin-like growth factor system components and the coupling of bone formation to resorption. Horm Res 1996; 45: 59-62.
86. Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, et al. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J Clin Invest 2000; 105(8):1085-93
87. Nash TJ, Howlett CR, Martin C, Steele J, Johnson KA, Hicklin DJ. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone 1994; 15: 203-208.
88. Kitoh H, Kitakoji T, Tsuchiya H, Mitsuyama H, Nakamura H, Katoh M, et al. Transplantation of marrow-derived mesenchymal stem cells and platelet-rich plasma during distraction osteogenesis-a preliminary result of three cases. Bone 2004; 35: 892-898.
89. Rose FRA, Hou Q, Oreffo RO. Delivery systems for bone growth factors-the new players in skeletal regeneration. J Pharm Pharmacol 2004; 56:415-427.
90. Boyne PJ. Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects. J Bone Joint Surg Am 2001; 83: S146-50.
91. Hussain M, Theise ND. Stem cell therapy for diabetes mellitus. Lancet 2004; 364: 203-205.
92. Mashima H, Ohnishi H, Wakabayashi Y, Mine T, Miyagawa J, Hanafusa T, et al. Betacellulin and actin A coordinately convert amylase-secreting pancreatic AR42J cells into insulin-secreting cells. J Clin Invest 1996; 97: 1647-1654.
93. Li L, Seno M, Yamada H, Kojima I. Betacellulin improves glucose metabolism by promoting conversion of intraislet precursor cells to β-cells in streptozotocin-treated mice. Am J Physiol Endocrinol Metab 2003;285: 577-583.
94. Mashima H, Shibata H, Mine T, Kojima I. Formation of insulin-producing cells from pancreatic acinar AR42J cells by hepatocyte growth factor. Endocrinology 1996; 137: 3969-3976.
95. Zulewski H, Abraham EJ, Gerlach MJ, Daniel PB, Moritz W, Muller B, et al. Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine and hepatic phenotypes. Diabetes 2001; 50: 521-533.
96. Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener JF. Insulinotropic hormone glucagons-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 2002; 143: 3152-3161.
97. Selander L, Edlund H. Nestin is expressed in mesenchymal and not epithelial population for pancreas and liver within the embryonic endoderm. Development 2001; 128: 871-881.
98. Zulewski H, Abraham EJ, Gerlach MJ, Daniel PB, Moritz W, Muller B, et al. Multipotential nestin-positive stem cells isolated from adult pancreatic islets differentiate ex vivo into pancreatic endocrine, exocrine, and hepatic phenotypes. Diabetes 2001; 50: 521-533.
99. Hui H, Wright C, Perfetti R. Glucagon-like peptide I induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 2001; 50: 785-796.
100. Deutsch G, Jung J, Zheng M, Lora J, Zaret KS. A bipotential precursor population for pancreas and liver within the embryonic endoderm. Development 2001; 128(6): 871-81
101. Gu D, Lee MS, Krahl T, Sarvetnick N. Transitional cells in the regenerative pancreas. Development 1994; 120(7): 1873-1881.
102. Hall PA, Lemoine NR. Rapid acinar to ductal transdifferentiation in cultured human exocrine pancreas. J Pathol 1992; 166: 97-133.
103. Reid LE, Walker NI. Acinar cell apoptosis and the origin of tubular complexes in ceralein-induced pancreatitis. Int J Exp Pathol 1999; 80: 205-215.
104. Lynch SE, Williams RC, Polson AM, Howell TH, Reddy MS, Zappa UE, et al. A combination of platelet derived and insulin-like growth factors enhances periodontal regeneration. J Clin Periodontol 1989; 16: 545-548.
105. Lynch SE, Buser D, Hernandez RA, Weber HP, Stich H, Fox CH, et al. Effects of the platelet-derived growth factor/insulin-like growth factor-I combination on bone regeneration around titanium dental implants. Results of a pilot study in beagle dogs. J Periodontol 1991; 62: 710-716.
106. Rutherford RF, Niekrash CE, Kennedy JE, Charette MF. Platelet-derived and insulin-like growth factors stimulate regeneration of periodontal attachment in monkeys. J Periodont Res 1992; 27: 285-290.
107. Giannobile WV, Finkelman RD, Lynch SE. Comparison of canine and non-human primate animal models for periodontal regenerative therapy: results following a single administration of PDGF/IGF-I. J Periodntol 1994; 65: 1158-1168.
108. Selvig KA, Wikesjo UME, Bogle GC, Finkelman RD. Impaired early bone formation in periodontal fenestration defects in dogs following application of insulin-like growth factor II. Basic fibroblast growth factor and transforming growth factor β1. J Clin Periodontol 1994; 21: 380-385.
109. Bowers G, Felton F, Middleton C, Glynn D, Sharp S, Mellonig J, et al. Histologic comparison of regeneration in human intrabony defects when osteogenin is combined with demineralized freeze-dried bone allograft and with purified bovine collagen. J Periodontol 1991; 62: 690-702.
110. Sigurdsson TJ, Nyhaard L, Tatakis DN, Fu E, Turek TJ, Jin L, et al. Periodontal repair in dogs: evaluation of rhBMP-2 carriers. Int J Periodontics Rest Dent 1996; 15: 525-537.
111. Wikesjo UM, Guglielmoni P, Promsudthi A, Cho KS, Trombelli L, Selvig KA, et al. Periodontal repair in dogs: Effects of rhBMP-2 concentration on regeneration of alveolar bone and periodontal attachment. J Clin Periodontol 1999; 26: 392-400.
112. Ripamonti U, Reddi AH. Periodntal regeneration: Potential role of bone morphogenic proteins. J Periodont Res 1994; 29: 225-235.
113. Giannobile WV, Ryan S, Shih MS, Su DL, Kaplan PL, Chan TC. Recombinant human osteogenic protein-1 (OP-1) stimulates periodontal wound healing in Class III furcation defects. J Periodontol 1998; 69: 129-137.
114. Selvig KA, Sorensen RG, Womey JM, Wikesjo UM. Bone repair following recombinant human bone morphogenetic protein-2 stimulated periodontal regeneration. J Periodontol 2002; 73(9): 1020-9.
115. Rossa C Jr, Marcantonio E, Cirelli JA, Marcantonio RA, Spolidorio LC, Fogo JC. Regeneration of Class III furcation defects with basic fibroblast growth factor (b-FGF) associated with GTR. A descriptive and histometric study in dogs. J Periodontol 2000; 71(5): 775-84.
116. Lyngstaadaas SP, Lundberg E, Ekdahl H, Andersson C, Gestrelius S. Autocrine growth factors in human periodontal ligament cells cultured on enamel matrix derivative. J Clin Periodontol 2001; 28: 181-188.
117. Van der Pauw MT, Van den Bos T, Everts V, Beertsen W. Enamel matrix-derived protein stimulates attachment of periodontal ligament fibroblasts and enhances alkaline phosphatase activity and transforming growth factor β release of periodontal ligament and gingival fibroblasts. J Periodontol 2000, 71: 31-43.
118. Kawase T, Okuda K, Yoshie H, Burns DM. Cytostatic action of enamel matrix derivative (EMDOGAIN) on human oral squamous cell carcinoma-derived SCC25 epithelia] cells. J Periodont Res 2000; 35: 291-300.
119. Giannobile WV, Somerman MJ. Growth and amelogenin-like factors in periodontal wound healing. A systematic review. Ann Periodontol 2003; 8: 193-204.
120. Marx RE, Carlson ER, Eichstaedt RN, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 84: 638-646.
121. Ganio C, Tenewitz FE, Wilson RC, Maules BG. The treatment of chronic nonhealing wounds using autologous platelet-derived growth factors. J Foot Ankle Sing 1993; 32: 263-268.
122. Obarrio JJ, Arauz-Dutari JI, Chamberlain TM, Croston A. The use of autologous growth factors in periodontal surgical therapy: Platelet gel biotechnology-Case reports. Int J Periodontics Rest Dent 2000; 20: 487-497.
123. Garg AK. The use of platelet-rich plasma to enhance the success of bone grafts around dental implants. Dent Implantol Update 2000; 11: 1-5.
124. Hoekman K, Vermorken JB. Incidence and prevention of nonhae-matological toxicity of high dose chemotherapy. Ann Med 1996; 28: 175-182.
125. Peterson DE. Oral toxicity of chemotherapeutic agents. Semin Oncol 1992; 19:478-491.
126. Sonis ST. Mucositis as a biological process: a new hypothesis for the development chemotherapy induced stomato-toxicity. Oral Oncol 1998; 34: 39-43.
127. Sonis ST, Lindquist L, vanVugt A, Stewart AA, Starn K, Qu GY, et al. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor β3. Canc Res 1994; 54: 1135-1138.
128. Dazzi C, Cairello A, Giovanis P, Monti M, Vertogen B, Leoni M, et al. Prophylaxis with GM-CSF mouthwashes does not reduce frequency and duration of severe oral mucositis in patients with solid tumors undergoing high-dose chemotherapy with autologous peripheral blood stem cell transplantation rescue: a double, blind, randomized, placebo-controlled study. Ann Oncol 2003; 14: 559-563.
129. Sonis S, Muska A, O'Brien J, van Vugt A, Langer-Safer SY, Keith J. Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur J Canc 1995; 3113: 261-266.
130. Biron P, Sebban C, Gourmet R, Chvetzoff G, Philip I, Blay JY. Research controversies in management of oral mucositis. Support Care Cancer 2000; 8: 68-71.
131. de Eguileor M, Tettamanti G, Grimaldi A, Perletti G, Congiu T, Rinaldi L, et al. Hirudo medicinalis: avascular tissues for clear-cut angiogenesis studies? Curr Pharm Des 2004; 10(16): 1979-88.
132. Flyvbjerg A, Khatir DS, Jensen LJ, Dagnaes-Hansen F, Gronbaek H, Rasch R. The involvement of growth hormone (GH), insulin-like growth factors (IGFs) and vascular endothelial growth factor (VEGF) in diabetic kidney disease. Curr Pharm Des 2004; 10(27): 3385-94.
133. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005; 11(8): 999-1016.